Login to Your Account



Basilea Has Successful Debut With $161M IPO in Switzerland

By Cormac Sheridan


Wednesday, March 31, 2004
Basilea Pharmaceutica AG raised gross proceeds of CHF205.8 million (US$161.2 million) in Europe's second significant biotechnology initial public offering of 2004. The Basel, Switzerland, drug development company sold 28.5 percent of its equity, or 2.1 million shares, priced at CHF98 per share, having initially set a price range of CHF90 to CHF115. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription